PL3062791T3 - Nowoczesne terapie zaburzeń uwagi i zaburzeń poznawczych oraz otępienia związanych z zaburzeniem neurodegeneracyjnym - Google Patents
Nowoczesne terapie zaburzeń uwagi i zaburzeń poznawczych oraz otępienia związanych z zaburzeniem neurodegeneracyjnymInfo
- Publication number
- PL3062791T3 PL3062791T3 PL14858402T PL14858402T PL3062791T3 PL 3062791 T3 PL3062791 T3 PL 3062791T3 PL 14858402 T PL14858402 T PL 14858402T PL 14858402 T PL14858402 T PL 14858402T PL 3062791 T3 PL3062791 T3 PL 3062791T3
- Authority
- PL
- Poland
- Prior art keywords
- attention
- neurodegenerative disorder
- cognitive disorders
- dementia associated
- novel treatments
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361896173P | 2013-10-28 | 2013-10-28 | |
| PCT/US2014/062644 WO2015066019A1 (en) | 2013-10-28 | 2014-10-28 | Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder |
| EP14858402.2A EP3062791B1 (en) | 2013-10-28 | 2014-10-28 | Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3062791T3 true PL3062791T3 (pl) | 2020-06-15 |
Family
ID=53005024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14858402T PL3062791T3 (pl) | 2013-10-28 | 2014-10-28 | Nowoczesne terapie zaburzeń uwagi i zaburzeń poznawczych oraz otępienia związanych z zaburzeniem neurodegeneracyjnym |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9861594B2 (pl) |
| EP (1) | EP3062791B1 (pl) |
| JP (1) | JP6607852B2 (pl) |
| KR (1) | KR102266696B1 (pl) |
| CN (1) | CN105848655B (pl) |
| AU (1) | AU2014342520B2 (pl) |
| CA (1) | CA2928429C (pl) |
| ES (1) | ES2769780T3 (pl) |
| IL (1) | IL245090A0 (pl) |
| PL (1) | PL3062791T3 (pl) |
| WO (1) | WO2015066019A1 (pl) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112375078B (zh) | 2014-12-18 | 2023-12-19 | 豪夫迈·罗氏有限公司 | 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途 |
| IL278063B2 (en) | 2018-06-21 | 2025-08-01 | Hoffmann La Roche | Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use |
| US11911373B2 (en) * | 2018-08-16 | 2024-02-27 | Technion Research & Development Foundation Limited | Attention evaluation and methods for medicating |
| WO2023172497A2 (en) * | 2022-03-07 | 2023-09-14 | Drexel University | Compounds, compositions, and methods for treating, ameliorating, and/or preventing cocaine use disorder |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL57240C (pl) | 1940-02-21 | |||
| US5352688A (en) | 1991-02-14 | 1994-10-04 | The Mount Sinai School Of Medicine Of The City University Of New York | Methods for the treatment of bradyphrenia in parkinson's disease |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| JPH07506823A (ja) | 1992-05-18 | 1995-07-27 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 記憶障害，性的機能不全およびパーキンソン氏病の治療のためのインドロン誘導体の使用 |
| AU2639299A (en) | 1998-02-24 | 1999-09-15 | Kyowa Hakko Kogyo Co. Ltd. | Remedies/preventives for parkinson's disease |
| DE60008697T2 (de) | 2000-03-28 | 2005-02-10 | Council Of Scientific And Industrial Research | Verfahren zur Herstellung von 4-(P-methoxyphenyl)-2-amino-butane und Insektizide |
| MXPA05013607A (es) | 2003-06-23 | 2006-04-06 | Neurochem Int Ltd | Candidatos de farmaco farmaceuticos mejorados y metodos para preparar los mismos. |
| US7825109B2 (en) | 2003-08-29 | 2010-11-02 | Ono Pharmaceutical Co., Ltd. | Compound capable of binding S1P receptor and pharmaceutical use thereof |
| CA2551944A1 (en) | 2003-12-15 | 2005-06-30 | Almirall Prodesfarma Ag | 2, 6 bisheteroaryl-4-aminopyrimidines as adenosine receptor antagonists |
| US8044100B2 (en) | 2004-12-22 | 2011-10-25 | Bellus Health Inc. | Methods and compositions for treating amyloid-related diseases |
| WO2006078239A1 (en) | 2005-01-18 | 2006-07-27 | University Of Florida | Compositions and methods for inhibiting pain |
| WO2006083692A2 (en) | 2005-01-28 | 2006-08-10 | Mount Sinai Schoool Of Medicine | Methods of identifying modulators of bromodomains |
| GB0505509D0 (en) | 2005-03-17 | 2005-04-27 | Ic Innovations Ltd | Compounds |
| US20070148238A1 (en) | 2005-06-23 | 2007-06-28 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| DE102005029468A1 (de) | 2005-06-24 | 2006-12-28 | Plt Patent & Licence Trading Ltd. | Verwendung von Inhibitoren der N-Methyltransferasen in der Therapie des Parkinson-Syndroms |
| US20090005568A1 (en) | 2005-08-18 | 2009-01-01 | Pharmacopeia Drug Discovery, Inc. | Substituted 2-aminothiazoles for treating neurodegenerative diseases |
| CA2652339A1 (en) | 2006-05-15 | 2007-11-22 | Senex Biotechnology, Inc. | Cdki pathway inhibitors as selective inhibitors of tumor cell growth |
| WO2008042755A2 (en) * | 2006-09-29 | 2008-04-10 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
| JP4142073B2 (ja) * | 2006-10-13 | 2008-08-27 | 株式会社コナミデジタルエンタテインメント | 表示装置、表示方法、ならびに、プログラム |
| TW200829241A (en) | 2006-10-30 | 2008-07-16 | Boehringer Ingelheim Int | Treatment of parkinson's disease |
| MX2009009121A (es) | 2007-03-05 | 2009-09-03 | Hoffmann La Roche | Aminoamidas como antagonistas de orexina. |
| WO2008113364A2 (en) | 2007-03-20 | 2008-09-25 | Recepticon Aps | Amino derivatives to prevent nephrotoxicity and cancer |
| CA2704199C (en) | 2007-11-01 | 2016-01-19 | Acucela Inc. | Amine derivative compounds for treating ophthalmic diseases and disorders |
| GB0808282D0 (en) | 2008-05-07 | 2008-06-11 | Medical Res Council | Compounds for use in stabilizing p53 mutants |
| US8486985B2 (en) | 2008-05-16 | 2013-07-16 | Allergan, Inc. | Selective subtype alpha 2 adrenergic agents and methods for use thereof |
| CN105968022A (zh) * | 2009-04-09 | 2016-09-28 | 考格尼申治疗股份有限公司 | 认知衰退的抑制剂 |
| US20110117214A1 (en) * | 2009-11-16 | 2011-05-19 | Auspex Pharmaceuticals, Inc. | Cyclohexyl urea modulators of d2 receptors and/or d3 receptors |
| WO2012021629A2 (en) | 2010-08-11 | 2012-02-16 | Philadelphia Health & Education Corporation | Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease |
| DE102011015842A1 (de) | 2011-03-30 | 2012-11-08 | Olaf Lichtenberger | Fluorphenyl- und Fluormethoxyphenylalkylamine und deren Anwendung |
| TW201305624A (zh) * | 2011-07-27 | 2013-02-01 | Hon Hai Prec Ind Co Ltd | 導光板修復方法 |
| AU2012298617B2 (en) * | 2011-08-25 | 2016-07-14 | Cognition Therapeutics, Inc. | Compositions and methods for treating neurodegenerative disease |
-
2014
- 2014-10-28 AU AU2014342520A patent/AU2014342520B2/en not_active Ceased
- 2014-10-28 PL PL14858402T patent/PL3062791T3/pl unknown
- 2014-10-28 CN CN201480071543.0A patent/CN105848655B/zh not_active Expired - Fee Related
- 2014-10-28 EP EP14858402.2A patent/EP3062791B1/en active Active
- 2014-10-28 KR KR1020167014290A patent/KR102266696B1/ko active Active
- 2014-10-28 CA CA2928429A patent/CA2928429C/en active Active
- 2014-10-28 US US15/028,654 patent/US9861594B2/en active Active
- 2014-10-28 JP JP2016526782A patent/JP6607852B2/ja not_active Expired - Fee Related
- 2014-10-28 WO PCT/US2014/062644 patent/WO2015066019A1/en not_active Ceased
- 2014-10-28 ES ES14858402T patent/ES2769780T3/es active Active
-
2016
- 2016-04-13 IL IL245090A patent/IL245090A0/en unknown
-
2017
- 2017-11-22 US US15/821,340 patent/US10695302B2/en active Active
-
2020
- 2020-06-04 US US16/892,467 patent/US11744810B2/en active Active
-
2023
- 2023-09-05 US US18/242,036 patent/US20240074993A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ718978A (en) | 2021-08-27 |
| EP3062791B1 (en) | 2020-01-08 |
| JP6607852B2 (ja) | 2019-11-20 |
| US20180092865A1 (en) | 2018-04-05 |
| US20240074993A1 (en) | 2024-03-07 |
| EP3062791A1 (en) | 2016-09-07 |
| AU2014342520A1 (en) | 2016-05-05 |
| ES2769780T3 (es) | 2020-06-29 |
| CN105848655A (zh) | 2016-08-10 |
| US20160256417A1 (en) | 2016-09-08 |
| US10695302B2 (en) | 2020-06-30 |
| US11744810B2 (en) | 2023-09-05 |
| KR20160067193A (ko) | 2016-06-13 |
| JP2016540737A (ja) | 2016-12-28 |
| KR102266696B1 (ko) | 2021-06-21 |
| EP3062791A4 (en) | 2017-08-16 |
| US9861594B2 (en) | 2018-01-09 |
| CN105848655B (zh) | 2019-11-08 |
| CA2928429A1 (en) | 2015-05-07 |
| HK1225973A1 (zh) | 2017-09-22 |
| US20200397721A1 (en) | 2020-12-24 |
| CA2928429C (en) | 2022-08-30 |
| IL245090A0 (en) | 2016-06-30 |
| AU2014342520B2 (en) | 2019-08-08 |
| WO2015066019A1 (en) | 2015-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201509101B (en) | Financial account with group authorization | |
| IL240337A0 (en) | Deviation alert | |
| EP3046470A4 (en) | Diagnosing and treating movement disorders | |
| GB201312279D0 (en) | Neurodegenerative disorders | |
| EP2953568A4 (en) | IDENTIFICATION OF PERIPHERAL NERVES | |
| IL237742A0 (en) | Laquinimod and pridofidine for the treatment of neurodegenerative diseases | |
| GB201305407D0 (en) | Media Distribution | |
| IL241100A0 (en) | Educational center | |
| PL2956071T3 (pl) | Zestaw do blokady nerwów obwodowych | |
| EP3026153A4 (en) | Thread production device, and aggregating part | |
| PT2986525T (pt) | Tampa com evidência de violaçâo | |
| GB201300538D0 (en) | Polycarbonates | |
| SG11201506356WA (en) | Dehydration-hydrolysis processes and catalysts therefor | |
| IL245090A0 (en) | New treatments for attention disorders, cognitive disorders and dementia related to a neurodegenerative disorder | |
| PL2823971T3 (pl) | Osłona obręczy koła oraz koło z taką osłoną | |
| IL276431A (en) | Treatment of the brain disorders and related symptoms | |
| SG11201509429UA (en) | Process for producing phenol and/or cyclohexanone | |
| PL3383851T3 (pl) | Pochodne dekstrorfanu o stłumionej nerwowej aktywności ośrodkowej | |
| GB2512235B (en) | Security apparatus with blocking element | |
| GB201420624D0 (en) | Security Lable | |
| SG11201509522UA (en) | Process for producing phenol and/or cyclohexanone | |
| SG11201603200VA (en) | Process for making phenol and/or cyclohexanone | |
| EP2909429A4 (en) | INTERVAL CONTROL VALVE WITH DIFFERENT RADIAL INTERIORS | |
| GB201413912D0 (en) | Circular foal feeder | |
| TWM476059U (en) | Hub |